Literature DB >> 22503289

A novel biochemically salvageable animal model of hyperammonemia devoid of N-acetylglutamate synthase.

Emilee Senkevitch1, Juan Cabrera-Luque, Hiroki Morizono, Ljubica Caldovic, Mendel Tuchman.   

Abstract

All knockout mouse models of urea cycle disorders die in the neonatal period or shortly thereafter. Since N-acetylglutamate synthase (NAGS) deficiency in humans can be effectively treated with N-carbamyl-l-glutamate (NCG), we sought to develop a mouse model of this disorder that could be rescued by biochemical intervention, reared to adulthood, reproduce, and become a novel animal model for hyperammonemia. Founder NAGS knockout heterozygous mice were obtained from the trans-NIH Knock-Out Mouse Project. Genotyping of the mice was performed by PCR and confirmed by Western blotting of liver and intestine. NCG and L-citrulline (Cit) were used to rescue the NAGS knockout homozygous (Nags(-/-)) pups and the rescued animals were characterized. We observed an 85% survival rate of Nags(-/-) mice when they were given intraperitoneal injections with NCG and Cit during the newborn period until weaning and supplemented subsequently with both compounds in their drinking water. This regimen has allowed for normal development, apparent health, and reproduction. Interruption of this rescue intervention resulted in the development of severe hyperammonemia and death within 48 h. In addition to hyperammonemia, interruption of rescue supplementation was associated with elevated plasma glutamine, glutamate, and lysine, and reduced citrulline, arginine, ornithine and proline levels. We conclude that NAGS deprived mouse model has been developed which can be rescued by NCG and Cit and reared to reproduction and beyond. This biochemically salvageable mouse model recapitulates the clinical phenotype of proximal urea cycle disorders and can be used as a reliable model of induced hyperammonemia by manipulating the administration of the rescue compounds.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22503289      PMCID: PMC3356441          DOI: 10.1016/j.ymgme.2012.03.004

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  35 in total

1.  Two hypomorphic alleles of mouse Ass1 as a new animal model of citrullinemia type I and other hyperammonemic syndromes.

Authors:  Carlos J Perez; Jean Jaubert; Jean-Louis Guénet; Kirstin F Barnhart; Catherine M Ross-Inta; Vicente C Quintanilla; Isabelle Aubin; Jimi L Brandon; Nancy W Otto; John DiGiovanni; Irma Gimenez-Conti; Cecilia Giulivi; Donna F Kusewitt; Claudio J Conti; Fernando Benavides
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

2.  Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene.

Authors:  O Shi; S M Morris; H Zoghbi; C W Porter; W E O'Brien
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

3.  Abnormal ornithine carbamoyltransferase in mice having the sparse-fur mutation.

Authors:  R DeMars; S L LeVan; B L Trend; L B Russell
Journal:  Proc Natl Acad Sci U S A       Date:  1976-05       Impact factor: 11.205

4.  Enzymatic synthesis of acetylglutamate by mammalian liver preparations and its stimulation by arginine.

Authors:  K Shigesada; M Tatibana
Journal:  Biochem Biophys Res Commun       Date:  1971-09       Impact factor: 3.575

5.  N-acetylglutamate synthetase (NAGS) deficiency: diagnosis, clinical observations and treatment.

Authors:  C Bachmann; J P Colombo; K Jaggi
Journal:  Adv Exp Med Biol       Date:  1982       Impact factor: 2.622

6.  Ammonia intoxication in rats: protection by N-carbamoyl-L-glutamate plus L-arginine.

Authors:  S Kim; W K Paik; P P Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1972-12       Impact factor: 11.205

7.  Mice lacking ornithine-delta-aminotransferase have paradoxical neonatal hypoornithinaemia and retinal degeneration.

Authors:  T Wang; A M Lawler; G Steel; I Sipila; A H Milam; D Valle
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

Review 8.  Arginine metabolism: nitric oxide and beyond.

Authors:  G Wu; S M Morris
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

9.  Adenovirus-mediated in vivo gene transfer rapidly protects ornithine transcarbamylase-deficient mice from an ammonium challenge.

Authors:  X Ye; M B Robinson; C Pabin; T Quinn; A Jawad; J M Wilson; M L Batshaw
Journal:  Pediatr Res       Date:  1997-04       Impact factor: 3.756

10.  Arginine: an essential amino acid for injured rats.

Authors:  E Seifter; G Rettura; A Barbul; S M Levenson
Journal:  Surgery       Date:  1978-08       Impact factor: 3.982

View more
  4 in total

Review 1.  Fifteen years of urea cycle disorders brain research: Looking back, looking forward.

Authors:  Kuntal Sen; Matthew Whitehead; Carlos Castillo Pinto; Ljubica Caldovic; Andrea Gropman
Journal:  Anal Biochem       Date:  2021-10-09       Impact factor: 3.365

2.  New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria.

Authors:  Jourdan A Andersson; Eric C Fitts; Michelle L Kirtley; Duraisamy Ponnusamy; Alex G Peniche; Sara M Dann; Vladimir L Motin; Sadhana Chauhan; Jason A Rosenzweig; Jian Sha; Ashok K Chopra
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

3.  Supramolecular Self-Assembly of Atomically Precise Silver Nanoclusters with Chiral Peptide for Temperature Sensing and Detection of Arginine.

Authors:  Wenjuan Wang; Zhi Wang; Di Sun; Shulin Li; Quanhua Deng; Xia Xin
Journal:  Nanomaterials (Basel)       Date:  2022-01-27       Impact factor: 5.076

4.  Genome-wide association study and targeted metabolomics identifies sex-specific association of CPS1 with coronary artery disease.

Authors:  Jaana A Hartiala; W H Wilson Tang; Zeneng Wang; Amanda L Crow; Alexandre F R Stewart; Robert Roberts; Ruth McPherson; Jeanette Erdmann; Christina Willenborg; Stanley L Hazen; Hooman Allayee
Journal:  Nat Commun       Date:  2016-01-29       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.